The Valley Desk

NCT04919226 · Interventional trial

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Overall registry status Active not recruiting

Phase 3

Conditions Neuroendocrine Tumors

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov